Effects of splanchnic vasoconstrictors on liver regeneration and survival after 90% rat hepatectomy

Dong-Sik Kim, Woong Bae Ji, Jae Hyun Han, Yoon Young Choi, Hyun Jin Park, Young-Dong Yu, Ju Young Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: Posthepatectomy liver failure is a serious complication and considered to be caused by increased portal pressure and flow. Splanchnic vasoactive agents and propranolol are known to decrease portal pressure. The aim of this study was to identify optimal candidates with potential for clinical use among somatostatin, terlipressin, and propranolol using rats with 90% hepatectomy. Methods: Rats were divided into 5 groups: sham operation (n = 6), control (n = 20), propranolol (n = 20), somatostatin (n = 20), and terlipressin group (n = 20). Seven-day survival rates and portal pressure change were measured, and biochemical, histologic, and molecular analyses were performed. Results: Portal pressure was significantly decreased in all 3 treatment groups compared to control. All treatment groups showed a tendency of decreased liver injury markers, and somatostatin showed the most prominent effect at 24 hours postoperatively. Histologic liver injury at 24 hours was significantly decreased in propranolol and terlipressin groups (P = 0.016, respectively) and somatostatin group showed borderline significance (P = 0.056). Hepatocyte proliferation was significantly increased after 24 hours in all treatment groups. Median survival was significantly increased in terlipressin group compared to control group (P < 0.01). Conclusion: Terlipressin is considered as the best candidate, while somatostatin has good potential for clinical use, considering their effects on portal pressure and subsequent decrease in liver injury and increase in liver regeneration.

Original languageEnglish
Pages (from-to)118-128
Number of pages11
JournalAnnals of Surgical Treatment and Research
Volume94
Issue number3
DOIs
Publication statusPublished - 2018 Mar 1

Fingerprint

Portal Pressure
Liver Regeneration
Viscera
Hepatectomy
Vasoconstrictor Agents
Somatostatin
Propranolol
Liver
Wounds and Injuries
Liver Failure
Hepatocytes
terlipressin
Control Groups

Keywords

  • Hepatectomy
  • Liver failure
  • Liver regeneration
  • Somatostatin
  • Terlipressin

ASJC Scopus subject areas

  • Surgery

Cite this

Effects of splanchnic vasoconstrictors on liver regeneration and survival after 90% rat hepatectomy. / Kim, Dong-Sik; Ji, Woong Bae; Han, Jae Hyun; Choi, Yoon Young; Park, Hyun Jin; Yu, Young-Dong; Kim, Ju Young.

In: Annals of Surgical Treatment and Research, Vol. 94, No. 3, 01.03.2018, p. 118-128.

Research output: Contribution to journalArticle

@article{10d19df9d42b4080acbd2f4fb2e546ce,
title = "Effects of splanchnic vasoconstrictors on liver regeneration and survival after 90{\%} rat hepatectomy",
abstract = "Purpose: Posthepatectomy liver failure is a serious complication and considered to be caused by increased portal pressure and flow. Splanchnic vasoactive agents and propranolol are known to decrease portal pressure. The aim of this study was to identify optimal candidates with potential for clinical use among somatostatin, terlipressin, and propranolol using rats with 90{\%} hepatectomy. Methods: Rats were divided into 5 groups: sham operation (n = 6), control (n = 20), propranolol (n = 20), somatostatin (n = 20), and terlipressin group (n = 20). Seven-day survival rates and portal pressure change were measured, and biochemical, histologic, and molecular analyses were performed. Results: Portal pressure was significantly decreased in all 3 treatment groups compared to control. All treatment groups showed a tendency of decreased liver injury markers, and somatostatin showed the most prominent effect at 24 hours postoperatively. Histologic liver injury at 24 hours was significantly decreased in propranolol and terlipressin groups (P = 0.016, respectively) and somatostatin group showed borderline significance (P = 0.056). Hepatocyte proliferation was significantly increased after 24 hours in all treatment groups. Median survival was significantly increased in terlipressin group compared to control group (P < 0.01). Conclusion: Terlipressin is considered as the best candidate, while somatostatin has good potential for clinical use, considering their effects on portal pressure and subsequent decrease in liver injury and increase in liver regeneration.",
keywords = "Hepatectomy, Liver failure, Liver regeneration, Somatostatin, Terlipressin",
author = "Dong-Sik Kim and Ji, {Woong Bae} and Han, {Jae Hyun} and Choi, {Yoon Young} and Park, {Hyun Jin} and Young-Dong Yu and Kim, {Ju Young}",
year = "2018",
month = "3",
day = "1",
doi = "10.4174/astr.2018.94.3.118",
language = "English",
volume = "94",
pages = "118--128",
journal = "Annals of Surgical Treatment and Research",
issn = "2288-6575",
publisher = "Korean Surgical Society",
number = "3",

}

TY - JOUR

T1 - Effects of splanchnic vasoconstrictors on liver regeneration and survival after 90% rat hepatectomy

AU - Kim, Dong-Sik

AU - Ji, Woong Bae

AU - Han, Jae Hyun

AU - Choi, Yoon Young

AU - Park, Hyun Jin

AU - Yu, Young-Dong

AU - Kim, Ju Young

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Purpose: Posthepatectomy liver failure is a serious complication and considered to be caused by increased portal pressure and flow. Splanchnic vasoactive agents and propranolol are known to decrease portal pressure. The aim of this study was to identify optimal candidates with potential for clinical use among somatostatin, terlipressin, and propranolol using rats with 90% hepatectomy. Methods: Rats were divided into 5 groups: sham operation (n = 6), control (n = 20), propranolol (n = 20), somatostatin (n = 20), and terlipressin group (n = 20). Seven-day survival rates and portal pressure change were measured, and biochemical, histologic, and molecular analyses were performed. Results: Portal pressure was significantly decreased in all 3 treatment groups compared to control. All treatment groups showed a tendency of decreased liver injury markers, and somatostatin showed the most prominent effect at 24 hours postoperatively. Histologic liver injury at 24 hours was significantly decreased in propranolol and terlipressin groups (P = 0.016, respectively) and somatostatin group showed borderline significance (P = 0.056). Hepatocyte proliferation was significantly increased after 24 hours in all treatment groups. Median survival was significantly increased in terlipressin group compared to control group (P < 0.01). Conclusion: Terlipressin is considered as the best candidate, while somatostatin has good potential for clinical use, considering their effects on portal pressure and subsequent decrease in liver injury and increase in liver regeneration.

AB - Purpose: Posthepatectomy liver failure is a serious complication and considered to be caused by increased portal pressure and flow. Splanchnic vasoactive agents and propranolol are known to decrease portal pressure. The aim of this study was to identify optimal candidates with potential for clinical use among somatostatin, terlipressin, and propranolol using rats with 90% hepatectomy. Methods: Rats were divided into 5 groups: sham operation (n = 6), control (n = 20), propranolol (n = 20), somatostatin (n = 20), and terlipressin group (n = 20). Seven-day survival rates and portal pressure change were measured, and biochemical, histologic, and molecular analyses were performed. Results: Portal pressure was significantly decreased in all 3 treatment groups compared to control. All treatment groups showed a tendency of decreased liver injury markers, and somatostatin showed the most prominent effect at 24 hours postoperatively. Histologic liver injury at 24 hours was significantly decreased in propranolol and terlipressin groups (P = 0.016, respectively) and somatostatin group showed borderline significance (P = 0.056). Hepatocyte proliferation was significantly increased after 24 hours in all treatment groups. Median survival was significantly increased in terlipressin group compared to control group (P < 0.01). Conclusion: Terlipressin is considered as the best candidate, while somatostatin has good potential for clinical use, considering their effects on portal pressure and subsequent decrease in liver injury and increase in liver regeneration.

KW - Hepatectomy

KW - Liver failure

KW - Liver regeneration

KW - Somatostatin

KW - Terlipressin

UR - http://www.scopus.com/inward/record.url?scp=85043269047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043269047&partnerID=8YFLogxK

U2 - 10.4174/astr.2018.94.3.118

DO - 10.4174/astr.2018.94.3.118

M3 - Article

AN - SCOPUS:85043269047

VL - 94

SP - 118

EP - 128

JO - Annals of Surgical Treatment and Research

JF - Annals of Surgical Treatment and Research

SN - 2288-6575

IS - 3

ER -